European Commission licences EUSA ’s advanced RCC treatment fotivda

Jazz Pharmaceuticals subsidiary EUSA Pharma ’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news